Dr. Korfmacher is a consultant for the pharmaceutical industry with the following areas of expertise: Drug Discovery Bioanalysis (BA) and Drug Metabolism and Pharmacokinetics (DMPK) as well as Mass Spectrometry (MS) Imaging. Dr Korfmacher has over 25 years of experience in the pharmaceutical industry, including working for the FDA (at the NCTR), as well as nearly two decades at Schering-Plough/Merck. Until 2018, Dr. Korfmacher was Director of Bioanalysis at Sanofi in Waltham MA. His group was responsible for the bioanalysis of small molecules and biologicals in preclinical samples as part of new drug discovery. Dr. Korfmacher has served as the chairperson of the North Jersey Mass Spectrometry Discussion Group. He is a member of three editorial boards: Rapid Communications in Mass Spectrometry; Current Drug Metabolism; and Drug Metabolism Letters and serves as an Associate Editor, pharmaceutical sciences, for the Journal of Mass Spectrometry. He has also edited three books on mass spectrometry and its use in drug discovery and drug metabolism arenas. He has written chapters in five additional books and has over 150 publications in scientific literature and has made over 80 presentations at various scientific forums. Dr Korfmacher received his MS and PhD in Analytical Chemistry from the U of Illinois (Urbana) and his BSCh from St. Louis U.